Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | IDE | P14735 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | HLCS | P50747 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17348120 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12852783 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL18413943 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12060446 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13380511 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13563116 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13525124 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14594154 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12119296 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13525109 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| EP-4276090-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2023-11-15 | — | — | EP | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| EP-3022206-B1 | EPHA4 INHIBITORS AS NEUROPROTECTIVE AGENTS | UNIV HONG KONG SCIENCE & TECH (HK) | 2023-07-12 | — | — | EP | disclosed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-20230048956-A1 | BIOTIN MOIETY-CONJUGATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING THE SAME | D&D PHARMATECH INC. (KR) | 2023-02-16 | — | — | US | disclosed |
| US-20230000834-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | D&D PHARMATECH, INC. (KP) | 2023-01-05 | — | — | US | disclosed |
| EP-1813946-A1 | BIOMATERIAL CONSTRUCT, ITS PRODUCING METHOD, BIOMATERIAL SUPPORT, TARGET MATERIAL PURIFYING METHOD, AFFINITY CHROMATOGRAPHY CONTAINER, SEPARATION CHIP, ANALYZING METHOD AND ANALYZING SEPARATOR FOR TARGET MATERIAL, BIOMATERIAL COMPLEX, AND ITS SUPPORT, SENSOR CHIP, SOLID SUPPORT WITH BIOMATERIAL FIXE | Mitsubishi Chemical Corporation (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20070154894-A1 | Labeling and non-enzymatic fragmentation of cDNA using a ribonucleoside triphosphate analog | AFFYMETRIX, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070154894-A1 | Labeling and non-enzymatic fragmentation of cDNA using a ribonucleoside triphosphate analog | AFFYMETRIX, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | ACTIVX BIOSCIENCES, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7220847-B2 | Detectable labeled nucleoside analogs and methods of use thereof | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220847-B2 | Detectable labeled nucleoside analogs and methods of use thereof | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20070087361-A1 | Solid support assay systems and methods utilizing non-standard bases | ERAGEN BIOSCIENCES, INC. | 2007-04-19 | — | — | US | disclosed |
| WO-2007038172-A2 | GUANIDINIUM CARRIERS | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078094-A1 | Guanidinium delivery carriers | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | DNPEP, CTRL, ARSA | TDP1 664/4885MEN1 4670/4885ABL1 710/4885 |
| US-20070078094-A1 | Guanidinium delivery carriers | SLC2A9, SLC29A2, SLC2A4 | TDP1 1606/4885MEN1 3995/4885ABL1 3517/4885 |
| US-20230000834-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | BTD, FABP2, PLPBP | TDP1 4587/4885MEN1 1379/4885ABL1 4705/4885 |
| US-20070154894-A1 | Labeling and non-enzymatic fragmentation of cDNA using a ribonucleoside triphosphate analog | RNGTT, POLRMT, BTD | TDP1 287/4885MEN1 4185/4885ABL1 4326/4885 |
| US-20230048956-A1 | BIOTIN MOIETY-CONJUGATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING THE SAME | VIP, BTD, HLCS | TDP1 4789/4885MEN1 1487/4885ABL1 3647/4885 |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | TDP1 3098/4885MEN1 493/4885ABL1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.